Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Company

Casper Pharma

Pharmaceutical intelligence for Casper Pharma with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.

Signals
1
Catalysts
0
Assets
1

Recent signals(1)

RegulatoryJuly 22, 2026

FDA Accepts NDA for Tiocystin by Casper Pharma

The FDA has accepted the New Drug Application (NDA) for Tiocystin (Tiopronin) submitted by Casper Pharma.

Upcoming catalysts

No catalysts indexed for this entity yet.

Regulatory activity(1)

RegulatoryJuly 22, 2026

FDA Accepts NDA for Tiocystin by Casper Pharma

The FDA has accepted the New Drug Application (NDA) for Tiocystin (Tiopronin) submitted by Casper Pharma.

Clinical activity

No signals indexed for this entity yet.

Competitive activity

No signals indexed for this entity yet.

Assets

Tiocystin →

Therapeutic areas

Cystinosis →
Rare Diseases →

Indications

Rare Diseases →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.